WNK2 and melanoma: Interestingly, the amplification of CCND1 is relatively rare in melanomas with BRAF-NRAS mutations and may have similar effects on melanoma cell growth as the activation of the mitogen-activated protein kinase (MAPK) signaling pathway resulting from BRAF and/or NRAS mutations [65, 66].